Investigating how nickel catalysts can improve the synthesis of pharmaceutical ingredients
Official title: Fundamental Studies of Ni-Catalyzed Organic Reactions
Funded at Yale University · NIH-11100311 · Data updated 2026-11-12
This study is exploring a new way to make important medicines using nickel instead of more expensive metals, which could lead to better and more affordable drugs for patients in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | September 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $242,272 |
| NIH project number | 3R35GM148260-02S1 |
| Project ID | NIH-11100311 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients who may benefit from this research are those who require new or improved pharmaceutical treatments for various health conditions.
✕Less likely to help
Patients who are not seeking new medications or those with conditions that are not addressed by the types of drugs being developed may not receive any benefit from this research.
What this research studies
This research focuses on using nickel catalysts to create active pharmaceutical ingredients (APIs) more sustainably than traditional precious metal catalysts. It aims to understand the mechanisms behind nickel-catalyzed reactions, particularly how they can form specific carbon-carbon bonds that are difficult to achieve otherwise. By synthesizing novel nickel complexes and studying their reactivity under various conditions, the research seeks to enhance the efficiency and effectiveness of drug synthesis. Patients may benefit indirectly through the development of new and improved medications resulting from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and sustainable methods for producing important medications.
How similar studies have gone: Other research has shown promise in using nickel catalysts for pharmaceutical synthesis, indicating that this approach has potential for success.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Hazari, Nilay — Yale University
- Study coordinator: Hazari, Nilay
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.